Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis-Reference-Cited by-同舟云学术

Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis

Published:2023-05 Issue:5 Volume:23 Page:e213-e221
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Ficek Joseph^ORCID,Kalaitzaki Eleftheria,Yuan Shuai Sammy,Tosolini Alessandra,Du Ling,Kremer Brandon E,Davy Katherine,Zhou Helen,Chen Tai-Tsang

Funder

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference42 articles.

1. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends;Huang;Lancet Haematol,2022

2. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma;Kumar;Lancet Oncol,2016

3. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis;Landgren;Bone Marrow Transplant,2016

4. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma;Munshi;Blood Adv,2020

5. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma;Munshi;JAMA Oncol,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What clinicians should know about surrogate end points in hematologic malignancies;Blood;2024-07-04

2. Very good partial remission predicts progression-free survival in patients with multiple myeloma;Oncohematology;2024-01-26

3. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma;Blood Advances;2023-12-29

4. Upfront or Deferred Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Triplet and Quadruplet Induction and Minimal Residual Disease/Risk-Adapted Therapy;Cancers;2023-12-05

5. Predictors of unsustained measurable residual disease negativity in transplant-eligible multiple myeloma patients;Blood Journal;2023-12-04